Novo Nordisk

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments.

CEO

Maziar Mike Doustdar

CEOMaziar Mike Doustdar

Employees

68,794

Employees68,794

Headquarters

Bagsværd, Capital Region

HeadquartersBagsværd, Capital Region

Founded

1923

Founded1923

Employees

68,794

Employees68,794

NVO Key Statistics

Market cap

172.59B

Market cap172.59B

Price-Earnings ratio

11.37

Price-Earnings ratio11.37

Dividend yield

3.11%

Dividend yield3.11%

Average volume

23.43M

Average volume23.43M

High today

$39.72

High today$39.72

Low today

$38.03

Low today$38.03

Open price

$38.47

Open price$38.47

Volume

43.93M

Volume43.93M

52 Week high

$93.80

52 Week high$93.80

52 Week low

$38.03

52 Week low$38.03

NVO News

The Motley Fool 36m

Could Novo Nordisk Help Turn $100,000 Into $1 Million in the GLP‑1 Gold Rush?

It would be a near-miracle gain. Novo Nordisk's (NVO 2.50%) shares have lagged the market over the past couple of years. However, the Denmark-based pharmaceuti...

Fox Business 12h

Novo Nordisk to slash list prices of Ozempic, Wegovy by up to 50%

Novo Nordisk on Tuesday announced plans to cut the list price of its popular diabetes and weight-loss drugs Ozempic and Wegovy by as much as 50% in the U.S. nex...

TipRanks 13h

Novo Nordisk price target lowered to DKK 309 from DKK 340 at Citi

Citi lowered the firm’s price target on Novo Nordisk (NVO) to DKK 309 from DKK 340 and keeps a Neutral rating on the shares. Published first on TheFly – the ul...

Analyst ratings

53%

of 34 ratings

Buy

38.2%

Hold

52.9%

Sell

8.8%

More NVO News

TipRanks 15h

BofA sees limited impact to Eli Lilly’s franchise from Novo’s GLP-1 price update

BofA says that today’s announcement that Novo Nordisk (NVO) plans to slash GLP-1 list prices offers a flashy headline, but in the firm’s view the update is unli...

CBS News 15h

Novo Nordisk to slash Wegovy and Ozempic prices starting in 2027

Novo Nordisk said Tuesday it will slash its prices for Wegovy and Ozempic beginning next year by up to 50%, highlighting the growing competition among pharmaceu...

The Wall Street Journal 16h

Stock in Rivals Novo Nordisk and Eli Lilly Slips

Novo Nordisk (NVO), (DK:NOVO.B) plans to slash U.S. list prices for its popular Wegovy and Ozempic by up to half starting next year. The Danish drugmaker a day...

CNBC 17h

Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients

Novo Nordisk on Tuesday said it plans to slash the monthly list prices of its popular obesity and diabetes drugs in the U.S. by up to 50% starting in 2027, in a...

Nasdaq 17h

Novo Nordisk To Cut US List Price For Wegovy, Ozempic And Rybelsus By Up To 50%

(RTTNews) - Novo Nordisk A/S (NVO) announced Tuesday that it will lower the list price or wholesale acquisition cost (WAC), Wegovy (semaglutide) injection 2.4 m...

MarketWatch 18h

Novo Nordisk and Eli Lilly shares both fall after Novo’s price-cut plan for Ozempic and Wegovy - MarketWatch

...

Barron's 18h

Novo Nordisk Is Cutting Ozempic and Wegovy Prices. The Stock Is Still Slumping.

Biotech and Pharma Novo Nordisk Is Cutting Ozempic and Wegovy Prices. The Stock Is Still Slumping. In this article NVO SPX LLY 3933 Novo Nordisk stock has plumm...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.